Main financial elements
• Financial visibility assured for the next 12 months, i.e. until the 4th quarter of 2024, supported by additional financing secured in the 1st half of 2023 and a reduction in operational expenses.
• Cash position of 15 million euros as of June 30, 2023, supplemented by the research tax credit of 5.4 million euros and additional financing of nearly 14 million euros secured after the first half of 2023, including a capital increase of 11.6 million euros through the financial bridge announced in the 2nd quarter of 2023 and amended (1) in September 2023 to support clinical programs.